Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Shivaprasad Manjappa, MDMBBS, Robert Fox, Jane Reese, Amin Firoozamand, MD, Hannah Schmikla, RN, Savannah Nall, RN, Merle Kolk, Paolo F Caimi, MD, James J. Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 35–37.

https://doi.org/10.1182/blood-2020-142115

Published: 2020

Journal Articles

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Amin Firoozmand, MD, Naveed Ali, MD, Nausheen Ahmed, MD, Pingfu Fu, Shufen Cao, George Brown, Hannah Schmikla, RN, James J. Driscoll, MD PhD, Timothy O'Brien, Paolo Caimi, MD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140800

Published: 2020

Journal Articles

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Ehsan Malek, MD, E. Ricky Chan, PhD, Daniel Qu, Jane Reese, Robert Fox, Byung-Gyu Kim, PhD DVM, Paolo F Caimi, MD, Marcos de Lima, MD, James J. Driscoll, MD PhD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142791

Published: 2020

Journal Articles

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Ehsan Malek, MD, Caner Saygin, MD, Rebecca Ye, Byung-gyu Kim, DVM, Fahrettin Covut, MD, Marcos De Lima, MD, James J. Driscoll, MD PhD

Blood (2016) 128 (22): 1146.

https://doi.org/10.1182/blood.V128.22.1146.1146

Published: 2016

Journal Articles

Counteracting PD-L1/PD-L2 Immune Suppression in Multiple Myeloma through Kinase Inhibition

James J. Driscoll, MD PhD, Irim Aslam, Ehsan Malek, MD

Blood (2016) 128 (22): 3295.

https://doi.org/10.1182/blood.V128.22.3295.3295

Published: 2016

Journal Articles

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Ehsan Malek, MD, Talib Dosani, MD, Raisa Pinto, MD, Fahrettin Covut, MD, Hugo Akabane, MD, James J. Driscoll, MD PhD, Marcos De Lima, MD

Blood (2016) 128 (22): 1862.

https://doi.org/10.1182/blood.V128.22.1862.1862

Published: 2016

Journal Articles

A Markov Model of Phase I Clinical Trials before or after Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Ehsan Malek, MD, Yihong Deng, MS, Mark Eckman, MD, Jeffrey Weldge, PhD, James J. Driscoll, MD PhD

Blood (2015) 126 (23): 3170.

https://doi.org/10.1182/blood.V126.23.3170.3170

Published: 2015

Journal Articles

Volumetric Parameters on Interim PET Predict Clinical Outcomes Better Than SUV max in Patients with Diffuse Large B-Cell Lymphoma

Ehsan Malek, MD, Arun Sendilnatha, MD, Mahender Yellu, MD MBBS, Andrew Petersen, MD, Mariano Fernandez-ulloa, MD, Marcos de Lima, MD, James J. Driscoll, MD PhD

Blood (2015) 126 (23): 1519.

https://doi.org/10.1182/blood.V126.23.1519.1519

Published: 2015

Journal Articles

Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance

James J. Driscoll, MD PhD, Ehsan Malek, MD

Blood (2015) 126 (23): 3021.

https://doi.org/10.1182/blood.V126.23.3021.3021

Published: 2015

Journal Articles

Microrna-29b Targets PSME4 to Inhibit Proteasome Activity and Prevent the Delivery of Aggresomes to Autophagosomes for Anti-Myeloma Benefit

Sajjeev Jagannathan, MS, Nikhil Vad, PhD, Mohamed A.Y. Abdel Malek, MD, Ehsan Malek, MD, James J. Driscoll, MD PhD

Blood (2014) 124 (21): 4703.

https://doi.org/10.1182/blood.V124.21.4703.4703

Published: 2014

Journal Articles

Correlation of Non-Coding RNA Expression with Response to Proteasome Inhibitors in Multiple Myeloma

Ehsan Malek, MD, Tahir Latif, MD, Anil Goud Jegga, DVM, MS, Sajjeev Jagannathan, MS, Nikhil Vad, PhD, Mohamed A.Y. Abdel Malek, MD, James J. Driscoll, MD PhD

Blood (2014) 124 (21): 3415.

https://doi.org/10.1182/blood.V124.21.3415.3415

Published: 2014

Journal Articles

Novel Therapeutic Strategies to Target Protein Quality Control Compartments in Multiple Myeloma

Mohamed A.Y. Abdel Malek, MD, Sajjeev Jagannathan, MS, Ehsan Malek, MD, Nikhil Vad, PhD, Douaa M. Sayed, MD PhD, Sahar A. Elgammal, MD PhD, Hanan G. Abd El-Azeem, MD PhD, Nabila M. Thabet, MD PhD, James J. Driscoll, MD PhD

Blood (2014) 124 (21): 3433.

https://doi.org/10.1182/blood.V124.21.3433.3433

Published: 2014

Journal Articles

Metformin Suppresses the GRP78-Dependent Delivery of Aggresomes to Autophagosomes to Enhance the Anti-Myeloma Benefit of Proteasome Inhibition

Sajjeev Jagannathan, MS, Nikhil Vad, PhD, Mohamed A.Y. Abdel Malek, MD, Ehsan Malek, MD, James J. Driscoll, MD PhD

Blood (2014) 124 (21): 433.

https://doi.org/10.1182/blood.V124.21.433.433

Published: 2014

Journal Articles

Induction of UBC9 and the Sumoylation Pathway in Multiple Myeloma Promotes Plasma Cell Growth and Correlates with Decreased Patient Survival.

James J. Driscoll, MD, PhD, Konstantinos Lefkimmiatis, PhD, Mariateresa Fulciniti, PhD, Rao Prabhala, PhD, Dheeraj Pelluru, PhD, Philip R. Greipp, MD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 3516.

https://doi.org/10.1182/blood.V110.11.3516.3516

Published: 2007

Journal Articles

T H 17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.

Rao Prabhala, PhD, Dheeraj Pelluru, PhD, Paola Neri, MD, Mariateresa Fulciniti, PhD, James J. Driscoll, MD, PhD, Song Weihua, MD, Simona Blotta, MD, Yu-Tzu Tai, PhD, Hiren Patel, BS, Yvonne A. Efebera, MD, Teru Hideshima, MD, PhD, Dhaminder Chauhan, PhD, John F. Daley, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 3517.

https://doi.org/10.1182/blood.V110.11.3517.3517

Published: 2007

Journal Articles

DNA Damage Induced Sumoylation of p53 in Multiple Myeloma: Implications for Cell Proliferation and Apoptosis.

James J. Driscoll, MD, PhD, Dheeraj Pelluru, PhD, Rao Prabhala, PhD, Konstantinos Lefkimmiatis, PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 112.

https://doi.org/10.1182/blood.V110.11.112.112

Published: 2007

Journal Articles

Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions.

Rao H. Prabhala, PhD, Paola Neri, MD, Mariateresa Fulciniti, PhD, Vanessa A. Therrien, Vidit Munshi, James J. Driscoll, MD,PhD, Masood A. Shammas, PhD, Teru Hideshima, MD,PhD, John F. Daley, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 659.

https://doi.org/10.1182/blood.V108.11.659.659

Published: 2006

Journal Articles

Physical and Functional Association of the MRN Complex with Human Telomerase in Multiple Myeloma.

James J. Driscoll, MD, PhD, Robert C. Bertheau, Masood A. Shammas, PhD, Rao H. Prabhala, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2006) 108 (11): 5076.

https://doi.org/10.1182/blood.V108.11.5076.5076

Published: 2006

NARROW

Impact of Daratumumab on Stem Cell Collection, Graft Composition and Engraftment Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant

Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs

Whole-Exome Sequencing Identifies a Somatic Cell Mutation Signature That Predicts Relapse Risk and Survival Probability in Multiple Myeloma

Rethinking Risk-Benefit Assessment for Phase I Multiple Myeloma Trials

Counteracting PD-L1/PD-L2 Immune Suppression in Multiple Myeloma through Kinase Inhibition

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

A Markov Model of Phase I Clinical Trials before or after Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Volumetric Parameters on Interim PET Predict Clinical Outcomes Better Than SUV max in Patients with Diffuse Large B-Cell Lymphoma

Pharmacogenomics of Bortezomib in Multiple Myeloma Patients Reveals That the Ubiquitin Ligase SCF-Skp2 Promotes Drug Resistance

Microrna-29b Targets PSME4 to Inhibit Proteasome Activity and Prevent the Delivery of Aggresomes to Autophagosomes for Anti-Myeloma Benefit

Correlation of Non-Coding RNA Expression with Response to Proteasome Inhibitors in Multiple Myeloma

Novel Therapeutic Strategies to Target Protein Quality Control Compartments in Multiple Myeloma

Metformin Suppresses the GRP78-Dependent Delivery of Aggresomes to Autophagosomes to Enhance the Anti-Myeloma Benefit of Proteasome Inhibition

Induction of UBC9 and the Sumoylation Pathway in Multiple Myeloma Promotes Plasma Cell Growth and Correlates with Decreased Patient Survival.

T H 17 Pathway and Associated Pro-Inflammatory Cytokines Promote Immune Dysfunction in Myeloma.

DNA Damage Induced Sumoylation of p53 in Multiple Myeloma: Implications for Cell Proliferation and Apoptosis.

Myeloma Microenvironment Controls T Regulatory Cell Activity: Potential Target for Therapeutic Interventions.

Physical and Functional Association of the MRN Complex with Human Telomerase in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only